Welcome to our dedicated page for Nexgel SEC filings (Ticker: NXGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trying to decode NexGel’s hydrogel business from hundreds of pages of SEC text? When a single factory produces electron-beam cross-linked gels for wound care, drug delivery, and cosmetics, every new 10-K or 8-K can feel like a chemistry paper. Investors want to spot FDA submission timelines, OEM contracts, or how much cash runway remains before the next production scale-up—but those details hide deep in footnotes.
Stock Titan’s AI turns that hunt into a two-minute read. Our platform ingests every NexGel quarterly earnings report 10-Q filing, NexGel insider trading Form 4 transactions, and proxy statement, then delivers plain-English summaries, real-time Form 4 alerts, and key-metric dashboards. Need the latest R&D spend? Click once. Wonder about NexGel executive stock transactions Form 4 ahead of a new cosmetic patch launch? We highlight them instantly. Even 8-K material events—factory upgrades, supply-chain shifts—arrive with context so you understand why they matter.
All filing types are here, updated the moment EDGAR releases them: 10-K annual reports for risk factors and revenue by product line, 10-Q for segment margins, 8-K for material events, Schedule 14A for NexGel proxy statement executive compensation, and every NexGel Form 4 insider transactions real-time. AI-powered summaries explain each note in simple terms, while expert commentary links disclosures to hydrogel capacity, regulatory milestones, and market expansion plans. Whether you search “understanding NexGel SEC documents with AI” or “NexGel earnings report filing analysis,” this page delivers the clarity and speed professionals expect.
NexGel, Inc. furnished an update via Form 8-K. The company provided a press release reporting results for the quarter ended September 30, 2025 and began using a new investor presentation. These materials were furnished under Items 2.02 and 7.01 and include Exhibit 99.1 (press release) and Exhibit 99.2 (investor presentation). The company stated the furnished information shall not be deemed filed for purposes of Section 18 of the Exchange Act.
NexGel, Inc. (NXGL) filed its Q3 2025 report, showing steady quarterly results and a continued focus on consumer brands alongside contract manufacturing. Revenue for the quarter was $2.934 million versus $2.940 million a year ago, while nine‑month revenue rose to $8.625 million from $5.647 million. Q3 gross profit was $1.243 million. The net loss attributable to stockholders was $653,000, or $0.08 per share, an improvement from $693,000 (or $0.11) last year.
The company disclosed substantial doubt about its ability to continue as a going concern. At September 30, cash was $938,000, alongside $920,000 of partnership restricted cash. Operating cash use for the nine months was $1.592 million, and working capital was $2.3 million. During Q3, NexGel raised equity proceeds of $963,000 by issuing 458,695 shares. Shares outstanding were 8,142,766 as of September 30, and 8,143,133 as of November 12, 2025.
Segment mix for Q3 included $1.918 million from consumer branded products and $907,000 from contract manufacturing.
NEXGEL (NXGL) reported an insider transaction on a Form 4. The Chief Executive Officer and Director sold 4,000 shares of common stock on 11/06/2025 at a $2.5211 weighted average price, pursuant to a Rule 10b5-1 trading plan.
Following the sale, the reporting person beneficially owns 367,692 shares, held directly. The price reflects multiple open-market sales within the $2.500–$2.5500 range.
NexGel, Inc. plans a special stockholder vote on an Authorized Share Increase. The proposal asks investors to approve—if and only if the Board later approves and implements—an amendment to raise authorized common stock from 25,000,000 to 1,000,000,000 shares, with total authorized capital increasing to 1,005,000,000 shares. The Board unanimously recommends a “FOR” vote.
The company cites future flexibility for capital raising, acquisitions, partnerships, and other corporate needs. Existing rights of common stock would remain the same, and preferred stock authorization stays at 5,000,000. The filing notes potential dilution if additional shares are issued in the future and acknowledges possible anti‑takeover effects, while stating the proposal is not in response to any control effort. Stockholders of record as of October 20, 2025 may vote; 8,142,766 common shares were outstanding as of that date.
NexGel, Inc. is asking stockholders to approve a major increase in authorized common shares—from 25,000,000 to 1,000,000,000—“if and only if” the Board later approves and implements the change. The vote will be held at 10:00 a.m. ET on November 26, 2025, at the company’s Langhorne, PA headquarters.
The Board unanimously recommends a “FOR” vote. The proposal requires the affirmative vote of a majority of total outstanding shares entitled to vote. Brokers have discretionary authority to vote on this proposal, and no appraisal rights apply.
The company cites future flexibility to raise capital, pursue acquisitions, joint ventures, and other corporate needs. The amendment itself has no immediate effect on ownership or voting power, but future issuances could dilute existing holders. As of October 20, 2025, shares outstanding were 8,142,766. If approved, the Board may effect the increase within twelve months by filing a Certificate of Amendment with Delaware.
NEXGEL, Inc. (NXGL) director Robert Henry Scott reported open-market sales under a Rule 10b5-1 plan. The earliest transaction date is
NEXGEL (NXGL)
He sold 1,600 shares on 10/02/2025 at $2.5000 per share and 2,400 shares on 10/03/2025 at a weighted average price of $2.5497, with individual trades ranging from $2.5000 to $2.6100. After these transactions, he beneficially owned 371,692 shares.
Nexgel, Inc. (NXGL) filed a Form 144 reporting a proposed sale of 16,000 common shares with an aggregate market value of $40,000.00. The shares were originally acquired on 10/15/2019 as compensation from the issuer. The filing lists approximately 8,067,580 shares outstanding and names The Charles Schwab Corporation as the broker with an approximate sale date of 10/02/2025 on NASDAQ. The filer also reported a prior sale of 4,000 shares on 08/28/2025 for gross proceeds of $9,896.00. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
NEXGEL director Henry Scott Robert sold 7,697 shares of the company's common stock on 09/25/2025 under a pre-established Rule 10b5-1 trading plan at a weighted average price of $2.3579 per share. The shares were originally purchased on 03/01/2024. After the sale, the reporting person beneficially owns 121,356 shares, held directly. The filer notes the sale prices ranged from $2.3500 to $2.3900 and offers to provide a breakdown of shares sold at each price if requested.
Form 144 notice for proposed sale of common stock. The filing shows 35,515 shares of common stock are proposed for sale through The Charles Schwab Corporation, with an aggregate market value of $108,451 and 8,067,580 shares outstanding. The securities were acquired as compensation on 02/15/2024 in a transaction described as "COMPENSATION / DEAL ACQUIRED BETWEEN: 2/15/24 TO 11/5/24" and payment is recorded as of 02/15/2024. The filer reports no securities sold during the past three months. The notice includes the standard representation that the seller is not aware of any undisclosed material adverse information.
FAQ
What is the current stock price of Nexgel (NXGL)?
What is the market cap of Nexgel (NXGL)?
